AI주식인사이트AI Stock Insight
C

팜젠사이언스

004720KOSPI

51.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Palmgen Science operates in pharmaceuticals, healthcare, and real estate leasing, achieving 16.54 billion KRW in pharmaceutical sales and 650 million KRW in healthcare sales in 2025. Key products include Esomax (for digestive disorders), Bardifin (hypertension treatment), and Kvasitin (hyperlipidemia treatment), with the company enhancing competitiveness through new drug development and quality improvements.

Number of Employees

229people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.43Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
-58.95Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
10.55Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼13.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -18.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 2,795Won52-week high 4,40052-week low 2,710
1-month return2.0Point

1m -5.89% (slight drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기업가치제고계획(자율공시) (PBR 개선 계획 제출 기업)2026-10-22